To evaluate direct costs of the use of insulin degludec (IDeg) in comparison to insulin glargine U100 (IGlar) in the treatment of Type 1 Diabetes Mellitus patients in a basal-bolus regimen (T1DM B / B ) in the Brazilian public healthcare system.
Figure 2 Overall Annual Costs, IDeg and IGlar, T1DM Objective
To evaluate direct costs of the use of insulin degludec (IDeg) in comparison to insulin glargine U100 (IGlar) in the treatment of Type 1 Diabetes Mellitus patients in a basal-bolus regimen (T1DM B / B ) in the Brazilian public healthcare system.
Methods
A one-year short-term model was developed to evaluate direct costs associated with the treatment of T1DM. The model measures resource use of insulins, needles, and the frequencies of hypoglycaemic events, use of blood glucose test strips and routine medical appointments for patients in treatment with IDeg and IGlar. Insulin dosing was derived from a meta-analysis of randomized clinical trials showing that IDeg was associated with 12% overall reduction in use of insulin compared to IGlar in T1DM patients. Rates of hypoglycaemia were also derived from a meta-analysis of randomized clinical trials. Unit costs were derived from official pricing and procedures reimbursement lists from the public healthcare perspective (i.e. CMED, BPS and SIGTAP). Costs presented in BRL/USD ($1.00USD-3.93BRL). Univariate deterministic sensitivity analysis was performed to assess robustness of results.
Introduction
Diabetes Mellitus is a chronic metabolic disorder with significant morbidity and mortality and relevant socioeconomic burden to healthcare systems. 
Clinical and Economic Inputs
Basal and bolus insulin dosing rates were both derived from a meta-analysis of randomized clinical trials (8) .
IDeg is associated with an overall reduction of 12% insulin use compared to IGlar in T1DM patients. 
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Methods

Model Design and Methodology
A one-year short-term model was developed to evaluate direct costs of T1DM patients in treatment with IDeg and IGlar. Randomized clinical trials of IDeg in comparison with IGlar had treat-to-target design and its results shows non-inferiority of IDeg vs. IGlar in HbA1C (9-11). Given that, this economic evaluation focuses on short-term clinical parameters (i.e. insulin dosing, hypoglycemic events) to assess cost implications to the healthcare system. Figure 1 demonstrates the model design and structure. The model comprises direct costs only, measuring the annual treatment costs within a 1-year time horizon, in the Brazilian public healthcare perspective. No discounts rates were applied. 
Sensitivity Analysis
Sensitivity analysis demonstrates that some variables have potential impact on the annual treatment costs (i.e. dose reduction in bolus insulin) compared to the base case scenario.
No critical variance in the annual costs is identified which confirms robustness of parameters.
To assess the robustness of results, a deterministic univariate sensitivity analysis was performed. The following uncertainty parameters were assessed: bolus insulin dose reduction considering both regular insulin and insulin aspart, daily use of needles in IGlar patients, additional SMBG tests, patients visiting the physician and IDeg and IGlar acquisition costs.
Results
Annual treatment costs were BRL5,557. 
Limitations
The model does not incorporate QALY measures to assess impact of clinical variables, such as hypoglycemic events and once-daily dosing, in patient adherence and quality of life. Economic burden of hypoglycemia might be underestimated as there is lack of data on its implications for the Brazilian healthcare system. Economic inputs are based on reference and reimbursement lists and might not fully represent regional and/ or specific cost settings. Some resource uses (i.e. needles and syringes) were based on assumptions. 
